News

Terumo Health Outcomes Announces Distribution Agreement for Caretaker Medical’s VitalStream® Non-Invasive Hemodynamic Monitoring

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced a new U.S. distribution agreement with Caretaker Medical to offer Caretaker Medical’s VitalStream wearable hemodynamic monitoring platform to hospitals nationwide. This agreement is yet another step in THO’s continued effort to bring forward-looking technologies to cardiovascular care teams seeking smarter, more efficient ways to monitor patient status and act sooner in the care process.

“We’re excited to partner with Terumo Health Outcomes to deliver impactful solutions for the early identification and improved treatment of shock and heart failure,” said Jeff Pompeo, CEO, Caretaker Medical. “Our VitalStream platform’s capability to deliver real-time, beat-by-beat physiological data – including continuous blood pressure and hemodynamics through a comfortable, non-invasive wearable – is central to this.”

Together, THO and Caretaker Medical are enabling clinicians to detect changes sooner and respond with confidence by eliminating invasive lines and bulky wires, especially in high-acuity cardiovascular settings like cath labs and cardiac step-down units – where timely and accurate intervention for these conditions is critical.

“Clinicians need reliable, non-invasive options for continuous monitoring, particularly in settings where invasive lines aren’t feasible or desired,” said Ghada Farah, President of Terumo Interventional Systems, Cardiac and Vascular Company at Terumo. “Caretaker’s VitalStream technology fits our mission of delivering tools that support earlier intervention and more informed decisions, while also helping hospitals improve clinical workflows and patient safety.”

THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by THO’s ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times. Learn more at www.terumohealthoutcomes.com.

 

Read more here.

Recent News

01/18/2026

Gerry Brunk Joins Focused Ultrasound Foundation’s Council

The Foundation is pleased to welcome Gerry Brunk to its Council, a committed group of goodwill ambassadors who partner with the Board of Directors and staff to offer guidance, raise funds, and generate awareness for focused ultrasound technology. Mr. Brunk co-founded Lumira Ventures, a North American healthcare venture capital firm, and serves as managing director in the firm’s Boston office. He has led investments in

01/12/2026

Nanochon closes $4.1M Seed Prime II Funding Round

Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects in the knee, has secured commitments to close an oversubscribed funding round, bringing its total capital raised to date to $11.3 million. The round was led by cultivate(MD), with significant contributions from The University of Virginia UVA Seed Fund, WSGR,

01/07/2026

ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: